Banque Pictet & Cie SA grew its position in Amgen, Inc. (NASDAQ:AMGN) by 105.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,114 shares of the medical research company’s stock after purchasing an additional 9,830 shares during the quarter. Banque Pictet & Cie SA’s holdings in Amgen were worth $3,291,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Capital Advantage Inc. lifted its stake in Amgen by 6.1% during the first quarter. Capital Advantage Inc. now owns 2,133 shares of the medical research company’s stock worth $350,000 after purchasing an additional 122 shares during the last quarter. Renaissance Group LLC increased its holdings in shares of Amgen by 5.1% during the first quarter. Renaissance Group LLC now owns 193,260 shares of the medical research company’s stock worth $31,708,000 after buying an additional 9,415 shares in the last quarter. Brave Asset Management Inc. increased its holdings in shares of Amgen by 57.4% during the first quarter. Brave Asset Management Inc. now owns 7,199 shares of the medical research company’s stock worth $1,181,000 after buying an additional 2,624 shares in the last quarter. Nelson Roberts Investment Advisors LLC acquired a new position in shares of Amgen during the first quarter worth $121,000. Finally, Gargoyle Investment Advisor L.L.C. increased its holdings in shares of Amgen by 0.6% during the first quarter. Gargoyle Investment Advisor L.L.C. now owns 17,665 shares of the medical research company’s stock worth $2,898,000 after buying an additional 100 shares in the last quarter. 78.38% of the stock is currently owned by institutional investors.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the sale, the executive vice president now directly owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock valued at $1,239,673 over the last ninety days. 0.19% of the stock is currently owned by insiders.
A number of analysts recently weighed in on the company. Credit Suisse Group restated a “neutral” rating and issued a $186.00 price objective (up from $177.00) on shares of Amgen in a report on Friday, September 29th. Royal Bank Of Canada assumed coverage on Amgen in a report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. Mizuho restated a “buy” rating and issued a $183.00 price objective (down from $195.00) on shares of Amgen in a report on Monday, August 21st. Morgan Stanley decreased their price objective on Amgen from $196.00 to $193.00 and set an “overweight” rating for the company in a report on Thursday, October 26th. Finally, Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $199.00 price target for the company in a report on Friday, October 27th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $190.22.
Shares of Amgen, Inc. (NASDAQ AMGN) traded down $2.26 during trading hours on Thursday, reaching $173.96. 3,102,079 shares of the company’s stock traded hands, compared to its average volume of 3,215,000. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen, Inc. has a 1 year low of $138.83 and a 1 year high of $191.10. The company has a market cap of $129,698.45, a P/E ratio of 14.20, a price-to-earnings-growth ratio of 2.59 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same period last year, the firm earned $3.02 EPS. The business’s quarterly revenue was down .7% compared to the same quarter last year. sell-side analysts forecast that Amgen, Inc. will post 12.66 earnings per share for the current fiscal year.
Amgen declared that its board has initiated a share repurchase plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s dividend payout ratio is currently 41.63%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.